Harmony Biosciences Holdings, Inc. (HRMY) Stock Price, Financials & Summary

Price chart

Aug 13Aug 18Aug 21Aug 26Aug 31Sep 3Sep 9Sep 14

Key dataSep 14, 2026

Open$41.93

From 52W high−3.08%

Volume915367.00

Market cap$2.42B

P/E (TTM)13.3x

P/S (TTM)2.5x

Div yield—

Key dataSep 14, 2026

Open

$41.93

From 52W high

−3.08%

Volume

915367.00

Market cap

$2.42B

ValuationView details →

P/E (Fwd)

10.4x

EV/EBITDA

6.9x

P/E (TTM)

13.3x

RSI (14)

60.5

MomentumView details →

1D Return

+0.05%

YTD Return

+11.19%

SummaryUpdated Jun 1, 2026

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is a commercial-stage pharmaceutical company founded in 2017 and based in Plymouth Meeting, Pennsylvania. The company went public in August 2020 and has established itself as a profitable biotechnology firm focused exclusively on developing and commercializing therapies for patients with rare neurological disorders. Since its founding, Harmony has built a robust pipeline of eight assets across three distinct therapeutic franchises, with its flagship product WAKIX generating over $2 billion in cumulative sales since launch.

Ask drillr about Harmony Biosciences Holdings, Inc. →

ValuationView details →

P/E (Fwd)

10.4x

P/E (TTM)

13.3x

EV/EBITDA

6.9x

EV/Sales

2.0x

P/S (TTM)

2.5x

P/B (TTM)

2.4x

ProfitabilityView details →

Gross Margin

75.42%

Net Margin

18.88%

EBITDA Margin

28.79%

ROE (TTM)

18.14%

ROA (TTM)

13.20%

Asset Turnover

0.73x

GrowthView details →

Revenue YoY

+24.25%

EPS YoY

−1.26%

FCF YoY

+37.17%

Revenue CAGR 3Y

+25.64%

EPS CAGR 3Y

−3.49%

EBITDA YoY

+4.28%

MomentumView details →

1D Return

+0.05%

YTD Return

+11.19%

1Y Return

+28.02%

RSI (14)

60.5

vs 50D SMA

+9.17%

vs 200D SMA

+20.89%

Capital & dividendView details →

Debt/Equity

0.15x

Current Ratio

3.48x

Quick Ratio

3.45x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

$1.28

EPS Surprise

33.89%

Beats (12Q)

8/12

Next Q EPS Est

$1.11

Avg Surprise (4Q)

−13.48%

Rev Surprise

4.19%

Financials snapshotView financials →

Revenue (TTM)

959.90M

Net Income (TTM)

181.27M

Op. CF (TTM)

355.08M

Next earningsNov 3, 2026 →

Latest newsMore news →

Aurora Investment Counsel acquired a new position in Harmony Biosciences Holdings, Inc., purchasing 65,148 shares valued at approximately $2.37 million, as disclosed in a recent SEC filing.26d ago

Harmony Biosciences highlighted record quarterly performance for its narcolepsy treatment WAKIX and outlined development plans across its orexin, epilepsy and pitolisant lifecycle-management programs during Piper Sandler's virtual CNS Symposium.32d ago

Similar companies

Braveheart Bio, Inc.BRVE Precigen, Inc.PGEN Clover Biopharmaceuticals, Ltd.02197.HK Vera Therapeutics, Inc.VERA 东亚药业605177.SH SELLAS Life Sciences Group, Inc.SLS Find similar companies →

Latest newsMore news →

Aurora Investment Counsel acquired a new position in Harmony Biosciences Holdings, Inc., purchasing 65,148 shares valued at approximately $2.37 million, as disclosed in a recent SEC filing.26d ago Harmony Biosciences highlighted record quarterly performance for its narcolepsy treatment WAKIX and outlined development plans across its orexin, epilepsy and pitolisant lifecycle-management programs during Piper Sandler's virtual CNS Symposium.32d ago Harmony Biosciences announced initial Phase 1 clinical data for its orexin-2 agonist BP-205, showing favorable pharmacokinetic and safety profiles, and plans to initiate Phase 1b and Phase 2 trials in 2026 and 2027.42d ago